Financial Performance - Revenue increased by approximately RMB 169.4 million or 83.1% to approximately RMB 373.3 million for the six months ended June 30, 2021[12] - Gross profit rose by approximately RMB 123.3 million or 81.0% to approximately RMB 275.6 million for the same period[12] - EBITDA increased by approximately RMB 83.7 million or 240.5% to approximately RMB 118.5 million for the six months ended June 30, 2021[12] - Profit attributable to equity holders increased by approximately RMB 65.7 million or 415.8% to approximately RMB 81.5 million for the same period[12] - The group's revenue for the six months ended June 30, 2021, was approximately RMB 373.3 million, an increase of about RMB 169.4 million or 83.1% compared to RMB 203.9 million for the same period in 2020[32] - Revenue from the sales of Jin Sangzi throat lozenges (OTC) was approximately RMB 333.3 million, up by RMB 148.1 million or 80.0% from RMB 185.2 million in the previous year[32] - Revenue from the sales of Jin Sangzi throat treasure series products reached approximately RMB 35.2 million, a significant increase of RMB 20.1 million or 133.1% compared to RMB 15.1 million in the same period last year[32] - Net profit for the six months ended June 30, 2021, was approximately RMB 81.5 million, an increase of approximately RMB 65.7 million or 415.8% compared to approximately RMB 15.8 million for the same period in 2020[44] - Profit before tax increased significantly to RMB 97,620,000, compared to RMB 22,698,000 in the previous year, marking a 329.5% growth[72] Product and Market Development - The flagship product, Jinsongzi throat lozenges (OTC), accounted for approximately 89.3% of total revenue for the six months ended June 30, 2021[20] - The Jinsongzi throat treasure series products contributed about 9.4% to total revenue for the same period, with exports to 17 countries and regions[22] - Other products, including ginkgo biloba tablets and herbal drinks, represented approximately 1.3% of total revenue for the six months ended June 30, 2021[22] - The company aims to expand its market presence and enhance product offerings in the herbal beverage segment[17] - The group aims to expand its market share in China's pharmaceutical and food markets by optimizing its product system and enhancing organizational capabilities[30] - The group plans to enhance its production capacity by constructing a new production base, which is expected to be operational in the second half of 2021, covering an area of approximately 60,000 square meters[31] - The new production base will feature fully automated production lines, improving production efficiency and product quality, thereby enhancing the company's overall competitiveness[31] Distribution and Sales Channels - The distribution network consists of over 680 distributors covering all provinces, autonomous regions, and municipalities in China, with an increase in the number of distributors compared to the previous year[26] - The company has established a flagship store on Tmall since October 2018, enhancing its online sales capabilities alongside retail pharmacy sales[27] - Online sales channels have been continuously developed, with the launch of the Jin Sangzi WeChat mini-program mall in early 2020, indicating a shift towards e-commerce[30] - The company has signed agency agreements with all 10 ASEAN countries, actively responding to the "Belt and Road" initiative[26] Research and Development - Since 1994, the company has successfully developed 31 new products, obtaining production licenses for 8 pharmaceutical products, 21 food products, 1 health food, and 1 medical device[23] - The R&D team comprises approximately 275 personnel as of June 30, 2021, focusing on independent research and collaboration with external research institutions[23] - The group will enhance its production capacity, expand its product portfolio, and improve R&D capabilities to boost competitiveness[55] Financial Position and Assets - As of June 30, 2021, the group's current assets net value was approximately RMB 728.7 million, compared to approximately RMB 696.4 million as of December 31, 2020[45] - Total interest-bearing bank borrowings and other borrowings increased to approximately RMB 210.3 million as of June 30, 2021, from approximately RMB 152.5 million as of December 31, 2020[46] - The group's debt-to-equity ratio increased from approximately 12.5% as of December 31, 2020, to approximately 16.7% as of June 30, 2021, primarily due to the increase in interest-bearing borrowings[49] - Total assets as of June 30, 2021, amounted to RMB 1,261,738,000, an increase from RMB 1,225,241,000 at the end of 2020[77] - Current assets totaled RMB 1,232,250,000, compared to RMB 1,156,208,000 at the end of 2020, reflecting a growth of 6.6%[75] Employee and Management Information - As of June 30, 2021, the group employed a total of 952 full-time employees, an increase from 902 full-time employees as of June 30, 2020[51] - Employee costs for the six months ended June 30, 2021, were approximately RMB 35.3 million, compared to RMB 32.2 million for the same period in 2020, reflecting an increase of about 9.6%[51] - The company has adopted a stock option plan to incentivize selected participants for their contributions to the group's development and growth[51] Shareholder Information - As of June 30, 2021, the total number of issued shares was 739,302,000, with major shareholders holding significant stakes[64] - Mr. Zeng Yong holds 511,963,200 shares, representing approximately 69.79% of the total issued shares[64] - The family trust controlled by Mr. Zeng Yong holds 453,025,800 shares, accounting for 61.28% of the total issued shares[70] - The senior management trust holds 58,937,400 shares, which is about 7.97% of the total issued shares[70] Dividends and Financial Instruments - The group did not declare any interim dividends for the six months ended June 30, 2021[59] - The group has not made any significant investments or acquisitions of subsidiaries, associates, or joint ventures during the six months ended June 30, 2021[52] - The group did not use any financial instruments to hedge its foreign exchange risks as of June 30, 2021[50]
金嗓子(06896) - 2021 - 中期财报